OTSKF Stock Latest News
Company AnnouncementsTaiho Completes U.S. NDA Submission for Zipalertinib Plus Chemotherapy in NSCLC6d ago
Company AnnouncementsOtsuka Holdings to Shift Governance Structure to Audit and Supervisory Committee Model2w ago
Company AnnouncementsOtsuka Holdings Completes ¥50 Billion Share Buyback and Plans Cancellation of Treasury Shares2w ago
Company AnnouncementsOtsuka Lifts Nine-Month Profits, Ups Dividend and EPS Outlook on Share Buybacks2w ago
Pre-EarningsOTSKF Earnings Report this Week: Is It a Buy, Ahead of Earnings?3w ago
Company AnnouncementsOtsuka’s VOYXACT Delivers Landmark Phase 3 Results in IgA Nephropathy3w agoCompany AnnouncementsOtsuka Unit Taiho Advances Zipalertinib NDA for EGFR Exon 20 NSCLC Under FDA RTOR1M ago
Company AnnouncementsOtsuka Holdings Nears Limit of ¥50 Billion Share Buyback Program1M ago
Company AnnouncementsOtsuka’s Zipalertinib Combo Delivers Strong Phase 3 Lung Cancer Results2M ago
Company AnnouncementsOtsuka Holdings Advances ¥50 Billion Share Buyback Program2M ago
Company AnnouncementsOtsuka’s Zipalertinib Combo Hits Phase 3 Goal in Targeted Lung Cancer Trial3M agoCompany AnnouncementsOtsuka’s VOYXACT Phase 3 Data Show Sustained Kidney Function Stabilization in IgA Nephropathy3M ago
Company AnnouncementsOtsuka Lifts 2026 Earnings Outlook and Raises Dividends on Strong Drug Sales3M ago
Company AnnouncementsOtsuka Holdings Delivers Strong Half-Year Earnings and Lifts 2026 Dividend Forecast3M ago
Pre-EarningsIs OTSKF a Buy, Before Earnings?3M ago
Company AnnouncementsOtsuka Lifts First-Half 2026 Earnings Forecast on Strong Drug Sales and Weak Yen3M ago
Company AnnouncementsOtsuka’s VOYXACT Achieves Key Phase 3 Success in IgA Nephropathy, Bolstering Long-Term Growth Strategy4M agoCompany AnnouncementsOtsuka Holdings Advances Share Buyback, Repurchases ¥29.9 Billion in Stock4M ago
Company AnnouncementsOtsuka’s VOYXACT Shows Kidney Function Preservation in Phase 3 IgA Nephropathy Trial5M ago






